Company Analysis
Sign in

Kailera Therapeutics, Inc. (KLRA)

Nasdaq: KLRA · Pharmaceutical Preparations · filing with the SEC since 2025
Full chart Alerts Compare
Grade5.8
◀ Past 6.0● Present 6.7▶ Future 5.0
8 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyas filed
Revenuen/a
Net incomen/a
Earnings per sharen/a
Operating cash flown/a
Cashn/a
Debtn/a
Shareholders’ equityn/a
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202663
Newest filingNov 4 · 10-Q
Annual reportn/a
Quarterly reportNov 4, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$159M
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
The record holds no annual figures yet.
As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Sep 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 14, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Aug 14, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Aug 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Aug 12, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 5, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Jul 8, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton KLRA · research, not advice